Scarica l'app Stockscreener
7.44
2.42%
-0.20
Dopo l'orario di chiusura:
7.44
Precedente Chiudi:
$7.64
Aprire:
$7.6
Volume 24 ore:
554.19K
Relative Volume:
1.30
Capitalizzazione di mercato:
$497.68M
Reddito:
$555.06M
Utile/perdita netta:
$-39.48M
Rapporto P/E:
-12.40
EPS:
-0.6
Flusso di cassa netto:
$29.05M
1 W Prestazione:
+3.83%
1M Prestazione:
+13.47%
6M Prestazione:
-26.41%
1 anno Prestazione:
-24.85%
Intervallo 1D:
$7.41
$7.74
Intervallo di 1 settimana:
$7.0301
$7.74
Portata 52W:
$5.81
$14.38
Bioventus Inc Stock (BVS) Company Profile
Nome
Bioventus Inc
Settore
Industria
Telefono
(919) 474-6700
Indirizzo
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Confronta BVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
7.44 | 480.29M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
131.87 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.11 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
390.88 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.02 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.88 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2022-11-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-11-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Iniziato | Craig Hallum | Buy |
| 2021-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2021-11-10 | Ripresa | JP Morgan | Overweight |
| 2021-07-01 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | JP Morgan | Overweight |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioventus Inc Borsa (BVS) Ultime notizie
RSI Reset May Fuel Rebound in Bioventus Inc.Portfolio Performance Report & Verified Entry Point Detection - kangso.co.kr
What makes Bioventus Inc. stock price move sharplyQuarterly Investment Review & Low Drawdown Momentum Ideas - Newser
Regression analysis insights on Bioventus Inc. performance2025 AllTime Highs & Safe Capital Growth Tips - Newser
Is it time to cut losses on Bioventus Inc.Earnings Recap Summary & Weekly High Return Stock Opportunities - Newser
Is Bioventus Inc. reversing from oversold territoryQuarterly Market Summary & High Accuracy Swing Entry Alerts - Newser
How to forecast Bioventus Inc. trends using time series2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Analyzing Bioventus Inc. with risk reward ratio chartsTrade Ideas & Low Risk Investment Opportunities - Newser
Why Bioventus Inc. stock attracts strong analyst attentionMarket Trend Summary & Free Weekly Watchlist of Top Performers - Newser
Bioventus Inc. stock outlook for YEARJuly 2025 Recap & AI Based Trade Execution Alerts - Newser
What recovery options are there for Bioventus Inc.July 2025 Institutional & High Accuracy Buy Signal Tips - Newser
Is Bioventus Inc. Forming a Bottom PatternJuly 2025 EndofMonth & Community Consensus Stock Picks - Newser
Detecting support and resistance levels for Bioventus Inc.July 2025 Gainers & Free Reliable Trade Execution Plans - Newser
Tick level data insight on Bioventus Inc. volatilityJuly 2025 PreEarnings & Verified Momentum Stock Watchlist - Newser
Published on: 2025-08-17 22:56:17 - Newser
Risk vs reward if holding onto Bioventus Inc.2025 Top Gainers & Safe Entry Momentum Tips - Newser
How to use Fibonacci retracement on Bioventus Inc.July 2025 Catalysts & Low Risk Growth Stock Ideas - Newser
Should you hold or exit Bioventus Inc. nowMarket Performance Summary & Daily Entry Point Alerts - Newser
Can a trend reversal in Bioventus Inc. lead to recovery2025 Top Decliners & Free Risk Controlled Daily Trade Plans - Newser
Real time pattern detection on Bioventus Inc. stock2025 Top Gainers & Daily Chart Pattern Signal Reports - Newser
How to monitor Bioventus Inc. with trend dashboards2025 Trade Ideas & Fast Gain Stock Tips - Newser
Advanced analytics toolkit walkthrough for Bioventus Inc.Forecast Cut & Real-Time Volume Spike Alerts - Newser
Tools to monitor Bioventus Inc. recovery probabilityQuarterly Profit Summary & Smart Money Movement Alerts - Newser
Is Bioventus Inc. stock entering bullish territoryJuly 2025 Trade Ideas & Free Real-Time Market Sentiment Alerts - Newser
What moving averages say about Bioventus Inc.Quarterly Profit Review & Community Driven Trade Alerts - Newser
Competitive Positioning of Bioventus Inc.: Is It Leading or Lagging2025 Momentum Check & Weekly Return Optimization Alerts - Newser
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative - simplywall.st
Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT - MSN
Shareholders Can Be Confident That Bioventus' (NASDAQ:BVS) Earnings Are High Quality - ca.finance.yahoo.com
New Product Launches: Will They Boost Bioventus Inc. Stock in 2025Quarterly Trade Report & AI Forecasted Entry and Exit Points - Newser
Is Bioventus (NASDAQ:BVS) A Risky Investment? - 富途牛牛
Bioventus: Strategic Initiatives and Growth Prospects Drive Buy Rating - TipRanks
Bioventus (NASDAQ:BVS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Bioventus Inc.’s Price Action Aligns with Quant Signals [July 2025 Technicals]Free Growth-Oriented Investment Plans - sundaytimes.kr
12 Best Medical Device Stocks to Buy According to Analysts - Insider Monkey
Bioventus at Canaccord Conference: Strategic Growth Path By Investing.com - Investing.com Australia
Bioventus at Canaccord Conference: Strategic Growth Path - Investing.com
Cantor Fitzgerald Reaffirms Their Buy Rating on Bioventus (BVS) - The Globe and Mail
Bioventus to Present at Canaccord Genuity Global Growth Conference on August 12, 2025. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Bioventus stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Bioventus stock - Investing.com
Bioventus Inc. Crosses 200 Day MA — Signal or NoiseTarget Return Focused Trade Insights Shared - metal.it
Bioventus Earnings Call: Strong Growth and Resilience - TipRanks
Should Investors Capitalize on Bioventus' Earnings Outperformance Amid Industry Lags? - AInvest
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Bioventus Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Bioventus Inc. (NASDAQ:BVS) Q2 2025 Earnings Call Transcript - Insider Monkey
Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance - MSN
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference - The Manila Times
Bioventus Q2 Earnings Call: Robust Growth and Strategic Resilience - AInvest
Exclusive: Bioventus CEO Reveals Future Growth Plans at Major Healthcare Conference - Stock Titan
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $15 - 富途牛牛
Bioventus Inc Azioni (BVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bioventus Inc Azioni (BVS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bartholdson John A. | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
72,045 |
| SUTTER MARTIN P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| STALNECKER SUSAN M | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
105,957 |
| NOHRA GUY P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
126,610 |
| NEELS GUIDO J | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| McMurry-Heath Michelle | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
74,698 |
| Ladone Mary Kay | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
78,981 |
| HAWKINS WILLIAM A | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
257,851 |
| Beyer Pat | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
76,436 |
| Singleton Mark Leonard | SVP & CFO |
Apr 11 '25 |
Sale |
7.57 |
3,875 |
29,334 |
141,088 |
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):